fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Inclisiran

All injection strengths: Limited Use (codes 732)

Leqvio · DIN 02518376 · 284 mg/1.5 mL · injection solution-1.5mL pre-filled syringe

Limited Use, Reason for Use code 732 requiredMarketed · checked November 19, 2026
StatusLimited Use, Reason for Use code 732 required
Write on scriptReason for Use code 732 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays: • ODB senior: $100/program-year deductible • Then up to $6.11 per prescription • Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Ontario Limited Use criteria, code 732
Reason for Use code 732 For the treatment of Heterozygous Familial Hypercholesterolemia (HeFH) in patients 18 years of age or older who meet the following criteria: 1. Definite or probable diagnosis of HeFH using the Simon Broome or Dutch Lipid Network criteria or genetic testing; AND 2. Unable to reach Low Density Lipoprotein Cholesterol (LDL-C) target (i.e., LDL-C less than 2.0 mmol/L for secondary prevention) or at least a 50% reduction in LDL-C from untreated baseline for primary prevention despite: A) Confirmed adherence to ezetimibe for at least a total of 3 months in combination with high dose statin (e.g., atorvastatin 80mg or rosuvastatin 40mg); OR B) Confirmed adherence to ezetimibe for at least a total of 3 months and inability to tolerate high dose statin defined as: (i) Inability to tolerate at least 2 statins with at least one started at the lowest starting dose; AND (ii) For each statin (two statins in total), dose reduction is attempted for intolerable symptom (myopathy) or biomarker abnormality (creatine kinase (CK) greater than 5 times the upper limit of normal) resolution rather than discontinuation of statin altogether; AND (iii) For each statin (two statins in total), intolerable symptoms (myopathy) or abnormal biomarker (creatine kinase (CK) greater than 5 times the upper limit of normal) changes are reversible upon statin discontinuation but reproducible by re-challenge of statins where clinically appropriate; AND (iv) One of the following: (I.) Other known determinants of intolerable symptoms or abnormal biomarkers have been ruled out; (II.) Patient developed confirmed and documented rhabdomyolysis; (III.) Patient is statin contraindicated i.e. active liver disease, unexplained persistent elevations of serum transaminases exceeding 3 times the upper limit of normal. Inclisiran will not be funded when used in combination with proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies. Treatment with inclisiran should be discontinued if the patient does not meet all of the following: 1. Patient is adherent to therapy. 2. Patient has achieved a reduction in LDL-C of at least 40% from baseline (4-8 weeks after initiation of inclisiran). 3. Patient continues to have a significant reduction in LDL-C (with continuation of inclisiran) of at least 40% from baseline since initiation of PCSK9 inhibitor. LDL-C should be checked periodically with continued treatment with PCSK9 inhibitors (e.g., every 6 months). Dosing: 284mg administered as a single subcutaneous injection: initially, again at 3 months, followed by every 6 months Coverage limit: LU Authorization Period: 1 year
No interchangeable product listed in the Ontario extract
Leqvio · DIN 02518376 Manufacturer: Novartis Pharma Canada Inc.; listing date 2025-10-31 Health Canada: Marketed since 2022-09-26 · brand LEQVIO · ATC C10AX16 INCLISIRAN · form Solution · route Subcutaneous · ingredients INCLISIRAN (INCLISIRAN) 284 MG/1.5ML · company Novartis pharmaceuticals canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Leqvio: Formulary list price $2898.90 per unit (the source does not state the unit; exact figure $2898.9048). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02518376)

Source record
DIN 02518376: Leqvio Raw flags: sec12=Y, sec3=Y Item: 240692003; group id 311; item number 0686; lccId 00418; manufacturer id NOV Source form: Inj Sol-1.5mL Pref Syr; strength: 284mg/1.5mL Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $2898.9048; ministry $2898.9048 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02518376 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100766
Shortage status: not checked (no credentials)

Other products in the same Health Canada class (C10A, C10AX): coverage varies; not interchangeable

  • Alirocumab (Praluent): limited Use 555
  • Evolocumab (Repatha): limited Use 527, 737
  • Ezetimibe (Ezetrol): limited Use 380, 381
  • Atorvastatin (Lipitor): general benefit
  • Bezafibrate (Bezalip): general benefit
  • Cholestyramine resin (Questran Light 4g Pk): general benefit, not a benefit

9 more in the class list below

Other drugs in the same formulary class (24:00 CARDIOVASCULAR DRUGS) and how they are covered

Matched class: 24:00 CARDIOVASCULAR DRUGS

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Public program routes: ODB 65 and over Covered without a code on the Ontario formulary: AMLODIPINE BESYLATE & ATORVASTATIN CALCIUM, ATENOLOL, ATORVASTATIN CALCIUM, BEZAFIBRATE, CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL & HYDROCHLOROTHIAZIDE, CILAZAPRIL & HYDROCHLOROTHIAZIDE, DIGOXIN, LABETALOL HCL, LOSARTAN POTASSIUM, LOSARTAN POTASSIUM & HYDROCHLOROTHIAZIDE, MINOXIDIL, OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL & HYDROCHLOROTHIAZIDE, PERINDOPRIL ERBUMINE, PERINDOPRIL ERBUMINE & INDAPAMIDE, PINDOLOL & HYDROCHLOROTHIAZIDE, PROPAFENONE HCL, ROSUVASTATIN CALCIUM, TELMISARTAN, TELMISARTAN & AMLODIPINE BESYLATE, TELMISARTAN & HYDROCHLOROTHIAZIDE, VALSARTAN & HYDROCHLOROTHIAZIDE Some products covered without a code (check the product listing): ACEBUTOLOL HCL, AMIODARONE HCL, AMLODIPINE, ATENOLOL & CHLORTHALIDONE, BENAZEPRIL, BISOPROLOL FUMARATE, CAPTOPRIL, CHOLESTYRAMINE RESIN, CILAZAPRIL, CLONIDINE HCL, COLESEVELAM HYDROCHLORIDE, DILTIAZEM HCL, DISOPYRAMIDE, DOXAZOSIN MESYLATE, ENALAPRIL MALEATE, FELODIPINE, FENOFIBRATE, FLECAINIDE ACETATE, FLUVASTATIN SODIUM, FOSINOPRIL SODIUM, GEMFIBROZIL, HYDRALAZINE HCL, IRBESARTAN, IRBESARTAN & HYDROCHLOROTHIAZIDE, ISOSORBIDE DINITRATE, LISINOPRIL, LISINOPRIL & HYDROCHLOROTHIAZIDE, LOVASTATIN, METHYLDOPA, METOPROLOL TARTRATE, MEXILETINE HCL, NADOLOL, NIFEDIPINE, NITROGLYCERIN, PINDOLOL, PRAVASTATIN SODIUM, PRAZOSIN HCL, PROPRANOLOL, QUINAPRIL, QUINAPRIL & HYDROCHLOROTHIAZIDE, RAMIPRIL, RAMIPRIL & HYDROCHLOROTHIAZIDE, SIMVASTATIN, SOTALOL HCL, TERAZOSIN HCL, TIMOLOL MALEATE, TRANDOLAPRIL, VALSARTAN, VERAPAMIL HCL 24:00 CARDIOVASCULAR DRUGS

FINERENONE

· 2 products · Limited Use, codes 700 · strengths: 10mg, 20mg · Tab

RANOLAZINE

· 2 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 500mg · ER Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 24:00 24:04 Cardiac Drugs

ACEBUTOLOL HCL

· 9 products · Listed, not a benefit (3), General benefit (6) · strengths: 100mg, 200mg, 400mg · Tab

AMIODARONE HCL

· 9 products · Listed, not a benefit (1), General benefit (8) · strengths: 200mg · Tab

AMLODIPINE

· 59 products · Limited Use, codes 645, 706 (1), Off-Formulary Interchangeable, not an ODB benefit (12), General benefit (46) · strengths: 1mg/mL, 2.5mg, 5mg, 10mg · Oral Sol, Tab

ATENOLOL

· 26 products · General benefit · strengths: 50mg, 100mg · Tab

BISOPROLOL FUMARATE

· 20 products · General benefit (18), Listed, not a benefit (2) · strengths: 1.25mg, 2.5mg, 5mg, 10mg · Tab

DIGOXIN

· 7 products · General benefit · strengths: 0.05mg/mL, 0.0625mg, 0.125mg · O/L, Tab

DILTIAZEM HCL

· 93 products · General benefit (91), Listed, not a benefit (2) · strengths: 120mg, 180mg, 240mg, 300mg, 360mg, 30mg, 60mg · ER Tab, LA Cap, SR Cap, Tab

DISOPYRAMIDE

· 3 products · Listed, not a benefit (1), General benefit (1), Temporary benefit (1) · strengths: 100mg · Cap

FLECAINIDE ACETATE

· 14 products · Listed, not a benefit (2), General benefit (12) · strengths: 50mg, 100mg · Tab

METOPROLOL TARTRATE

· 28 products · Listed, not a benefit (6), General benefit (22) · strengths: 100mg, 200mg, 50mg · LA Tab, Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 24:04 and 90 more
Full class listing Related classes: Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
Indications Primary hypercholesterolemia LEQVIO® (inclisiran injection) is indicated as an adjunct to lifestyle changes, including diet, to further reduce low-density lipoprotein cholesterol (LDL-C) level in adults with the following conditions who are on maximally tolerated dose of a statin, with or without other LDL-C -lowering therapies: • Heterozygous familial hypercholesterolemia (HeFH), or • Non-familial hypercholesterolemia with atherosclerotic cardiovascular disease (ASCVD) The effect of LEQVIO on cardiovascular morbidity and mortality has not been determined. 1.1 Pediatrics Pediatrics (<18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. 1.2 Geriatrics Geriatrics (≥ 65 years of age): Of the 1833 patients treated with inclisiran in the Phase III program, 981 (54%) patients were 65 years of age and older, while 239 (13%) patients were 75 years of age and older. Elderly subjects with heterozygous familial hypercholesterolemia were however less represented (22% were aged ≥ 65 years). No overall differences in safety or efficacy were observed between patien… https://pdf.hres.ca/dpd_pm/00085938.PDF PM date: 2026-08-27 Source product: LEQVIO; DIN 02518376; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
Program rules and quotes
Public program routes (Ontario context; residency, health-card/OHIP requirements and enrolment must be confirmed from the quoted rules): ODB 65 and over (seniors path) Eligibility: You may qualify for the Ontario Drug Benefit (ODB) program when you turn 65 years old. (ontario.ca, August 18, 2026 ↗) Eligibility: The Ontario Drug Benefit program is for Ontario residents only and prescriptions must be filled in an Ontario pharmacy to be covered. (ontario.ca, August 18, 2026 ↗) Eligibility: Individual annual net income threshold Program year August 1, 2026 to July 31, 2027: $25,480 This applies to a senior who: does not have a spouse has a married spouse with whom they no longer live in a conjugal relationship has a spouse living in a long-term care home or community home for opportunity (ontario.ca, July 2, 2026 ↗) Eligibility: Combined annual net income requirement Program year August 1, 2026 to July 31, 2027: $42,290 This applies to a senior who has a spouse, other than a spouse described. (ontario.ca, July 2, 2026 ↗) Eligibility: See the first-year deductible table. (ontario.ca, August 18, 2026 ↗) What it pays / costs: the first $100 of total prescription costs each program year (August 1 to July 31 the following year) (ontario.ca, August 18, 2026 ↗) What it pays / costs: up to $6.11 for each prescription filled or refilled (after paying the deductible) (ontario.ca, August 18, 2026 ↗) What it pays / costs: Seniors enrolled in the Seniors Co-Payment Program have no annual deductible and a reduced co-payment of up to $2. (ontario.ca, August 18, 2026 ↗) Enrolment: "We will send you a letter about 3 months before your 65th birthday to let you know you will automatically join the Ontario Drug Benefit program on the first day of the month after you turn 65 years old." (ontario.ca, August 18, 2026 ↗) Enrolment: "To enroll in the Seniors Co-Payment Program, a senior must submit an application to that program and qualify under certain income eligibility thresholds." (ontario.ca, August 18, 2026 ↗)
First year on ODB? The deductible depends on birth month
For your first year of Ontario Drug Benefit program eligibility, depending on the month you turn 65, the deductible may be lower than $100. That’s because the amount of the deductible is based on the number of months between your official start date (the first day of the month after you turn 65) and July 31 (the last day of the Ontario Drug Benefit program year). For example, if you turned 65 on April 15, your official start date would be May 1. Counting from May 1 to July 31 your deductible for the first year would be $25. Use this chart below to see what the deductible will be in your first year:
Month you were bornAmount of first-year deductible
July$100.00
August$91.67
September$83.33
October$75.00
November$66.67
December$58.33
January$50.00
February$41.67
March$33.33
April$25.00
May$16.67
June$8.33

Ontario source · 2026-08-18